Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Emergent BioSolutions (EBS) PT Raised to $130 at Cantor Fitzgerald Following EPS
February 19, 2021 7:39 AM ESTCantor Fitzgerald analyst Brandon Folkes raised the price target on Emergent BioSolutions (NYSE: EBS) to $130.00 (from $110.00) while maintaining an Overweight rating.
The analyst commented, "Post 4Q20, we reiterate our Overweight rating and raise our 12-month price target to $130, from $110. EBS continues to be... More
Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus
February 18, 2021 4:20 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $3.67, $0.48 better than the analyst estimate of $3.19. Revenue for the quarter came in at $583 million versus the consensus estimate of $563.94 million.
Emergents financial and operational performance in 2020 reflects the impact we are making in addressing the... More
